TABLETS CONTAINING BREXPIPRAZOL
A tablet formulation with brexpiprazole and specific fillers addresses solubility and stability issues, enhancing the drug's dissolution and bioavailability.
Patent Information
- Application Number
- TR202318024
- Authority / Receiving Office
- TR · TR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-12-22
- Publication Date
- 2026-10-21
- Estimated Expiration
- 2043-12-22
AI Technical Summary
Brexpiprazole, an antipsychotic and antidepressant, has poor water solubility, leading to stability and dissolution issues in existing formulations, which affects its therapeutic efficacy.
A tablet formulation containing brexpiprazole with specific particle sizes and a combination of fillers like corn starch, lactose monohydrate, and microcrystalline cellulose, along with binders and lubricants, is produced through dry granulation, ensuring uniformity and improved solubility.
The formulation achieves enhanced stability, dissolution profile, and bioavailability of brexpiprazole, addressing the solubility and stability issues of the drug.
Abstract
Description
1 TARIFF TABLETS CONTAINING BREXPIPRAZOL Field of Invention The present invention relates to a tablet containing brexpiprazole or a salt thereof and at least two fillers. It is related, and here one of the fillers is corn starch and brexpiprazole, in 5 particles between 1 µm and 35 µm. It has a particle size of d (0.9). Also, the present invention is simple, fast, cost-effective, time-saving. It is also related to a profitable and industrially viable process. Background of the Invention Brexpiprazole is a partial agonist of the serotonin 5-HT1A receptor and dopamine D2 and D3 receptors. It functions. Brexpiprazole is used in 10 cases of schizophrenia, depression, and other central nervous system disorders. in the treatment of and management of behavioral and psychological symptoms or mental health issues associated with neurodegenerative disease. Use described in the prophylaxis and / or treatment of impulsive symptoms associated with the disease. It has been done. Brexpiprazole is a compound represented by the following Formula I and its chemical name is 7-[4-[4-(1-benzothiophene- 4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one. 15 Formula I Brexpiprazole is used orally for the treatment of schizophrenia and as an antidepressant in major depressive disorder. It is an antidepressant and antipsychotic medication marketed under the brand name Rexulti® as an adjunct therapy. REXULTI tablets are intended for oral administration and are available in doses of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. It is available. The product was approved in the US in 2015 for the indications mentioned above and is currently... Treatment of agitation associated with Alzheimer's disease and treatment of PTSD (post-traumatic stress disorder) It is in phase III trials. Brexpiprazole has poor water solubility. Its low solubility is the drug's greatest limitation. Therefore, solubility is important in a formulation containing brexpiprazole. 25 2 Patent application number WO2019121849 describes a) brexpiprazole as the active ingredient and b) at least 5% by weight of the same substance. A pharmaceutical in tablet form containing (by weight %) pregelatinized starch (PGS). It relates to composition. The invention involves the dry granulation of a mixture of components to produce granules. and relates to tablet preparation methods, which involve compressing granules into a tablet shape. Patent application EP3545950A1 describes a pharmaceutical product containing a granulate with brexpiprazole. This relates to the composition, where the granule is a carrier, a brexpiprazole in a solvent system. It is obtained through wet granulation using a granulation liquid that is a solution. In previous techniques, the low solubility of brexspiprazole was approached in various ways. However, the dissolution... We found that the efforts to improve its profile could cause some stability problems. Therefore, it is necessary to have the desired stability, dissolution profile, hardness, and compressibility, in other words, 10 brexspiprazole, or a tablet that can overcome the disadvantages seen in the active ingredient. There is still a need for a film-coated tablet containing a salt of this. The formulation is simple and convenient. It was developed using standard techniques, which is a costly method. Detailed Description of the Invention The main aim of the present invention is to eliminate the problems caused by the active substance brexspiprazole. The goal is to eliminate the previous related technique and gain additional advantages over it. Another objective of the present invention is to achieve content uniformity and compressibility at the desired level. The aim is to provide a tablet containing brexpiprazole that has a good dissolution profile. Another objective of the present invention is to produce a tablet containing brexpiprazole with improved high stability. to provide. 20 The following particle sizes are crucial for the formulation of brexspiprazole or one of its salts. We found that this particularly has a positive effect on solubility properties and powder homogeneity. The tablets produced have the desired dissolution profile. The powder is more homogeneous. Obtained from a more homogeneous powder. The tablets produced have a more ideal content uniformity. Therefore, they provide better bioavailability. (Filler) Using corn starch as a preservative helps to achieve the desired solubility profile. 25 In addition to this, corn starch also ensures that the tablet does not easily break down in the formulation. As used here, 'particle size' refers to the laser diffraction method (e.g., Malvern Mastersizer 2000). cumulative volume size tested by any traditionally accepted method (such as analysis). 3 It means distribution. The term d (0.9) refers to the dimension in which 90% of the particles are finer by volume. does. According to one arrangement of the present invention, one tablet contains brexpiprazole or one of its salts and at least two It contains fillers, one of which is corn starch and brexpiprazole. It has a particle size d (0.9) between 1 µm and 35 µm. 5 In one arrangement of the invention, brexpiprazole or one of its salts, with a particle size between 3 µm and 28 µm, more preferably. It has a particle size d (0.9) between µm and 18 µm. According to a regulation of the present invention, the amount of brexpiprazole or one of its salts, in total The percentage of the composition is between 0.1% and 10.0% by weight. According to one arrangement of the present invention, the other filler materials used are lactose monohydrate, 10 microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc, polysorbate 80, xylitol or mixtures thereof 15 is selected from the group that is formed. According to this arrangement of the present invention, another filler is lactose monohydrate, microcrystalline. They are cellulose or mixtures thereof. According to this arrangement of the present invention, another filler is lactose monohydrate and microcrystalline. It is cellulose. 20 According to this arrangement of the present invention, the amount of filler in the tablet constitutes a percentage of the total composition. It is 80.0% to 95.0% by weight. Preferably, it is 85.0% to 92.0% by weight of the total composition. According to this arrangement of the present invention, the tablet may also contain binders, dispersants, lubricants or combinations thereof. It contains at least one pharmaceutically acceptable excipient selected from a group of mixtures. Suitable binders include polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, 25 carbomers, cellulose acetate phthalate, chitosan, starch, starch mucilage, acacia mucilage, dextracts, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, 4 polymethacrylates, aluminum hydroxide, stearic acid, sucrose, polyoxyethylene-alkyl ethers, pullulan or It is selected from a group consisting of mixtures of these. According to this arrangement of the present invention, the binder shall be polyvinylpyrrolidone or hydroxypropyl cellulose or They are mixtures of these. According to this arrangement of the present invention, the amount of binder in the tablet is 5 by weight of the total composition. It ranges from 1.0% to 10.0%. Preferably, it is 2.0% to 6.0% by weight of the total composition. Suitable dispersants include sodium starch glycolate, crospovidon, and cross-linked carboxymethyl cellulose. (croscarmellose sodium), low-substitution hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, Guar gum, sodium alginate, alginic acid, magnesium aluminum silica, poloxamer, sodium glycine It is selected from the group consisting of carbonates or mixtures thereof. 10 According to this arrangement of the present invention, the dispersant is crospovidon. This ensures the desired dissolution profile. It helps to ensure this. According to this arrangement of the present invention, the amount of dispersant in the tablet is a percentage of the total composition. 1.0% to 10.0% by weight, preferably 2.0% to 4.6% by weight. Suitable lubricants include sodium stearyl fumarate, magnesium stearate, calcium stearate, zinc stearate, talc, 15 boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmitosulfate, It is selected from the group consisting of sodium lauryl sulfate or mixtures thereof. According to this arrangement of the present invention, the lubricant is sodium stearyl fumarate. This is a tablet This improves the powder processing properties of the formulation. Furthermore, it reduces interparticle friction, thus improving powder processing. It increases the flow. According to this arrangement of the present invention, the amount of lubricant in the tablet is equal to the weight of the total composition. It ranges from 0.1% to 3.0%. According to this arrangement of the present invention, the tablet in question is used as a core tablet and further It is then coated with a film coating to obtain a film-coated tablet form. 25 According to this arrangement of the present invention, the tablet in question is used as a mini-tablet and then... The tablets are packed into capsules. 0.25 mg mini-tablets are placed in different capsules. Easy access is provided to every dose of the brexpiprazole product. According to this arrangement of the present invention, the tablet includes the following: ▪ D90 is brexspiprazole or one of its salts, with a particle size smaller than approximately 35 microns. ▪ Corn starch ▪ Crospovidon ▪ Sodium stearyl fumarate 5 According to this arrangement of the present invention, the tablet includes the following: ▪ D90 is brexspiprazole or one of its salts, with a particle size smaller than approximately 35 microns. ▪ Lactose monohydrate ▪ Microcrystalline cellulose ▪ Corn starch 10 ▪ Crospovidon According to this arrangement of the present invention, the tablet is a simple and cost-effective method of aging. It is prepared by the granulation method. A solvent is used in the process. Suitable solvents include water, ethanol, dichloromethane, 0.1N HCl, isopropyl alcohol, benzyl alcohol, and propylene glycol. polyethylene glycol, glycerin, glycerin triacetate, diethylene glycol monoethyl ether, glycerol, propylene carbonate or 15 It is selected from a group consisting of mixtures of these. According to this arrangement of the present invention, the solvent used throughout wet granulation is water. 25 Example 1: Tablet 6 Components Quantity (total) formulation by weight % CORE TABLET inside Components - % by weight Inside the MINI TABLET Components - % by weight Brexpiprazole 0.1 -10.0 3.33 1.00 Lactose monohydrate 40.0 – 60.0 56.11 56.80 Microcrystalline cellulose 5.0 – 25.0 11.11 12.00 Corn starch 10.0 - 32.0 22.22 23.00 Polyvinylpyrrolidone 1.0 -10.0 3.56 3.60 Crospovidone 1.0 -10.0 3.00 3.00 Sodium stearyl fumarate 0.1 - 3.0 0.67 0.60 Water ymymym TOTAL 100 100 100 A process for Example 1; a) Mixing lactose monohydrate, corn starch, and microcrystalline cellulose, b) Mixing brexpiprazole and crospovidon, c) Mixing the mixture in step (a) with the mixture in step (b) by geometric dilution. d) Sifting the mixture to a 0.9 mm sieve and then mixing, 5 e) Preparation of a granulation solution with polyvinylpyrrolidone and water (preferably 10% PVP), f) Granulating the mixture in step (d) with the granulation solution in step (e), g) Sifting the mixture to 2 mm and then mixing it. h) Drying the mixture in the fluidized bed until its moisture content is below 2%, i) Sieving the dry mixture to a 1 mm sieve and then mixing, 10 j) Adding sodium stearyl fumarate and then mixing, k) Pressing the total mixture into tablet form. Ideally, it comes in tablet or mini-tablet form, and these mini-tablets are packed into capsules. Ideally, the tablet is coated with a film to obtain a film-coated tablet. 15 7 Example 2: Tablet Components Quantity (total) formulation by weight % CORE TABLET inside Components - % by weight MINI TABLET components inside - by weight % Brexpiprazole 0.1 -10.0 3.33 1.0 Lactose monohydrate 40.0 – 60.0 55.67 56.4 Microcrystalline cellulose 5.0 – 25.0 11.11 12.0 Corn starch 10.0 - 32.0 22.22 23.0 Hydroxypropyl cellulose 1.0 -10.0 4.00 4.0 Crospovidone 1.0 -10.0 3.00 3.0 Sodium stearyl fumarate 0.1 - 3.0 0.67 0.6 Water ymymym TOTAL 100 100 100 A process for Example 2; a) Mixing lactose monohydrate, corn starch, and microcrystalline cellulose, b) Mixing hydroxypropyl cellulose, brexpiprazole and crospovidon, 5 c) Mixing the mixture in step (a) and the mixture in step (b) by geometric dilution, d) Sifting the mixture to a 0.9 mm sieve and then mixing it. e) Adding water (approximately 30-35 grams) and granulating, f) Sifting the mixture to a 2 mm sieve and then mixing it. g) Drying the mixture in the fluidized bed until the moisture content is below 2%, 10 h) Sieving the dry mixture to 1 mm and then mixing it, i) Adding sodium stearyl fumarate and then mixing, j) Pressing the total mixture into a tablet. Ideally, it comes in tablet or mini-tablet form, and these mini-tablets are packed into capsules. Ideally, the tablet is coated with a film to obtain a film-coated tablet.
Claims
1 REQUESTS 1) Brexiprazole or one of its salts, a tablet containing at least two fillers and a lubricant. Its distinguishing feature is that one of the fillers is corn starch, and brexpiprazole is absorbed by a membrane of 1 µm. It has a particle size of d (0.9) between 35 µm and the lubricant is sodium stearyl It is fumarate. 2) According to claim 1, it is a tablet containing brexpiprazole or one of its salts, in a concentration of 3 µm to 28 µm. It should have a particle size d (0.9) between 5 µm and 18 µm, preferably. 3) According to Claim 1, it is a tablet and its characteristic feature is that the other fillers used are lactose monohydrate. microcrystalline cellulose, mannitol, pregelatinized starch, ammonium alginate, calcium bicarbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc, polysorbate 80, xylitol or It is the selection of a group consisting of mixtures of these. 4) Tablet according to claim 1 or 3, the characteristic being that another filler is lactose monohydrate, It is microcrystalline cellulose or mixtures thereof. 5) According to Claim 1, it is a tablet, and its characteristic is that it is a tablet, and also includes connectors, distributors or their components. at least one pharmaceutically acceptable excipient selected from the group of mixtures It includes. 6) Tablet according to claim 5, characterized by its binders being polyvinylpyrrolidone and carboxymethylcellulose. sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, cornstarch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, hydrogenated Vegetable oil type I, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, aluminum hydroxide, stearic acid, sucrose, polyoxyethylene-alkyl ethers, pullulan or their derivatives It is the selection of a group consisting of mixtures. 7) Tablet according to claim 5 or 6, characterized by the binder being polyvinylpyrrolidone or hydroxypropyl It is cellulose or mixtures thereof. 2 8) Tablet according to claim 5, containing dispersants, sodium starch glycolate, crospovidon, cross-linking agents. bound carboxymethyl cellulose (croscarmellose sodium), low-substitution hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, alginic acid, magnesium aluminum silica, poloxamer, sodium glycine carbonate, or mixtures thereof. It is the selection from the group. 9) Tablet according to claim 5 or 8, characterized by the fact that the dispenser is crospovidon. 10) According to Claim 1, it is a tablet, and its characteristic is that the tablet in question is used as a core tablet. and then it is coated with a film to obtain a film-coated tablet form. 11) According to Claim 1, it is a tablet, and its characteristic is that the tablet in question can be used in the form of mini-tablets and It is then filled into a capsule. 12) It is a tablet according to claim 1, and its characteristic is that the tablet includes the following: ▪ D90 is brexspiprazole or one of its salts, with a particle size smaller than approximately 35 microns. ▪ Corn starch ▪ Crospovidon ▪ Sodium stearyl fumarate 13) A tablet according to claim 1 or 5, and its characteristic is that the tablet includes the following: ▪ D90 is brexspiprazole or one of its salts, with a particle size smaller than approximately 35 microns. ▪ Lactose monohydrate ▪ Microcrystalline cellulose ▪ Corn starch ▪ Crospovidon
